The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial
Keith A.A. Fox, FRCP*,1,
Elliott M. Antman, MD, FACC
,1,*,
Gilles Montalescot, MD
,1,
Stefan Agewall, MD
,
Bhupathi SomaRaju, MD||,
Freek W.A. Verheugt, MD, FACC¶,
Jose Lopez-Sendon, MD, FACC#,
Hanoch Hod, MD, FACC**,
Sabina A. Murphy, MPH
and
Eugene Braunwald, MD, MACC
,1
* University of Edinburgh, Edinburgh, United Kingdom
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Womens Hospital and Harvard Medical School, Boston, Massachusetts
Institut de Cardiologie, Pitie-Salpetriere University Hospital, Paris, France
Coronary Care Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
|| CARE Hospital, Hyderabad, India
¶ University Hospital Nijmegen, Nijmegen, the Netherlands
# Hospital Universitario La Paz Madrid, Madrid, Spain
** Heart Institute, Sheba Medical Center, Tel Hashomer, Israel.

View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Relationship Between Creatinine Clearance and Outcomes
Panels A to D plot the outcomes shown as estimated from a univariate regression model treating creatinine clearance (CrCl) as a continuous variable. MI = myocardial infarction.
|
|

View larger version (75K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Death or Nonfatal Recurrent MI at 30 Days in Strata of CrCl According to Treatment Assignment
CrCl = creatinine clearance; ENOX = enoxaparin; MI = myocardial infarction; ORadj = odds ratio adjusted for baseline risk; UFH = unfractionated heparin.
|
|
Copyright © 2007 by the American College of Cardiology Foundation.